Truist analyst Joon Lee initiated coverage of Praxis Precision Medicines with a Buy rating and $10 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PRAX:
- Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International Congress
- Praxis Precision Medicines to present analyses from Essential1 study
- Billionaire Steve Cohen Loads Up on These 2 ‘Strong Buy’ Penny Stocks — Here’s Why Wall Street Sees Over 500% Upside Potential
- Praxis Precision price target lowered to $7 from $15 at H.C. Wainwright
- Praxis Precision Medicines reports Q2 EPS (49c), consensus (65c)